Executive summary
U.S. Patent 9,611,283 claims broad, structure-defined small-molecule compounds of Formula (I) used to treat ALK-driven cancers by targeting (i) specific ALK point mutations (SEQ ID NO: 2 position subsets), (ii) ALK-fusion proteins with defined mutation pairs, and (iii) cancers refractory or intolerant to named ALK inhibitors, including crizotinib and named comparators CH5424802 and ASP3026. The independent claims are predominantly method-of-treatment and method-of-inhibition claims using a functional treatment frame tied to Formula (I) and to mutation-selected ALK biology. Claim scope is dominated by (1) wide Markush freedom in substituent variables (Rd, Re, Rh, Ra2, Rg, Rg2, Rg1, Rb2, Rb4, Ra1, Ra2, R5A-R5D, Y, X1/X2, R1/R2/R4), (2) relatively narrow biological restriction in some claims (specific mutation position/amino-acid substitutions), and (3) additional reach in later dependent claims that list extended mutation sets beyond the initial independent claim examples. Based on the claim text supplied, the patent’s actionable landscape risk is centered on whether any competitor’s ALK inhibitor candidate falls within the Formula (I) Markush envelope and, if not, whether design-arounds can avoid the mutation-by-mutation method framing (and comparator-refractory/intolerance qualifiers).
United States Patent 9,611,283: what is claimed, what’s the Formula (I) scope, and where are the legal fault lines?
Core claim structure (independent claims 1, 4, 5, 6, 7, 8, 9, 10)
Across the independent set, the patent claims methods that share a common scaffold:
- Biological gating: an ALK-driven cancer (full-length ALK, ALK fusion protein, or a mutant ALK mutant/cell) with specified mutation(s) in SEQ ID NO: 2 amino-acid position(s), or alternatively a functional limitation (refractory to specific inhibitors; intolerant to specific inhibitors; refractory to wild-type ALK inhibitors).
- Therapy element: administering a therapeutically effective amount of a compound of Formula (I) (or a pharmaceutically acceptable salt), or contacting cells with the same compound for inhibition of proliferation.
- Compound definition: Formula (I) is defined by layered Markush variables controlling heterocycles, substituents, and ring closures.
Why the Markush language is the scope driver
The claim’s chemistry is written as a high-coverage Markush construct. Even when biological mutation lists are narrow, the chemical genus is broad enough that the primary infringement question becomes: does the accused compound satisfy the variable definitions for Rd/Re/Rh/Ra2/Rg/Rg2/Rg1/Rb2/Rb4/Ra1/R5A/R5B/R5C/R5D/Y/X1/X2/R1/R2/R4 and corresponding ring-closure rules?
Key chemistry scope components include:
-
Pyrimidine core with variable substituents and ring constraints involving the pyrimidine ring atoms.
-
Rd can be H, C1-4 alkyl, or halo; Re is H (with a ring-closure alternative for Rd+Re forming a 5- or 6-membered heteroatom ring with N/S/O).
-
Rh is H, C1-4 alkyl, or halo.
-
Ra2 is H, C1-6 alkoxy, C3-6 alkenyloxy, or C3-6 cycloalkyloxy.
-
Rg is —P(O)(R3A)(R3B) (a phosphine oxide motif), where R3A/R3B can be H or many hydrocarbyl/heteroalkyl types or can cyclize to a substituted heterocycle.
-
Rg2 can be H/halo/CN/alkyl/alkenyl/alkynyl/cycloalkyl/cycloalkenyl/cycloalkynyl/heteroalkyl, with an alternative ring-closure constraint to a 5- to 7-member heterocycle containing P/N/O/S.
-
Rg1 limited to H, F, or a 5- or 6-membered heterocycle with 1 or 2 N.
-
Rb2 limited to H, F, or a 5- or 6-membered ring with 1-3 N or O.
-
Rb4 is the most diverse substituent category: H/halo/CN/alkyl/alkenyl/alkynyl/cycloalkyl/cycloalkenyl/cycloalkynyl/heteroalkyl or alkoxy/alkenyloxy/cycloalkyloxy, or specific functional group motifs including carboxamide-like and carbamate-like structures:
- —OC(O)N(R5A)(R5B)
- —NR5CC(O)OR5D
where R5A/R5B/R5C/R5D are broadly selected from H/alkyl/alkenyl/alkynyl/heteroalkyl and can cyclize.
-
Ra1 is also highly variable through:
- direct options (H/halo/—CN/—NO2/—R1/—OR2/O—NR1R2/NR1R2/NR1—NR1R2/… up to phosphate-like YP(=O)(YR1)(YR2) and sulfonamide/sulfones),
- plus a conditional ring-forming option with Rb4 to create a 6-member heterocycle containing 1-3 N or O.
Legal fault lines
- Incorporation by reference of Formula (I): because the method claims depend on Formula (I) definition, any narrowing, construction, or validity issue affecting the chemical definition impacts all method claims.
- Biology lists vs functional categories: some claims are mutation-position constrained; others are refractory/intolerant framed, which can reach broader patient populations for the same chemical genus.
- Redundancy in claim sets: claims 1-9 largely reuse the same Formula (I) definition, with different ALK framing and mutation sets. This increases cumulative coverage for similar clinical embodiments and complicates straightforward design-arounds.
How broad is the Formula (I) Markush in US 9,611,283 and what substitution variables drive infringement?
Direct answer
The patent defines a large chemical genus through extensive Markush substitution variables (at least: Rd/Re/Rh/Ra2/Rg/Rg2/Rg1/Rb2/Rb4/Ra1/R5A-R5D/Y/X1/X2/R1/R2/R4), plus multiple ring-closure contingencies. The chemical scope is broad enough that the competitive relevance is highest when an accused compound was designed within the same chemotype family containing a phosphine oxide (—P(O)(R3A)(R3B)) and the corresponding heterocycle substituent pattern.
Chemistry variables most likely to be “claim mapping” hotspots
- —P(O)(R3A)(R3B): if a competitor omits the phosphine oxide motif or uses a different phosphorus oxidation state/core, it can materially reduce literal match risk.
- Rb4 / Ra1 / ring-closure: because Ra1 can be a wide array of electrophilic/functional substituents and Rb4 can be either varied substituents or amide/carbamate-like groups, the mapping of those positions is typically the most litigated portion in chemotype Markush patents.
- Rg1 and Rb2 restrictions: these are somewhat constrained (specific allowed heterocycles, N counts), potentially narrowing parts of the genus.
- Rd/Re ring closure: conditional ring formation rules (Rd+Re to form a 5- or 6-member hetero ring with N/S/O) can create sharp non-infringement edges if a competitor’s substituent pattern breaks the ring-closure condition.
What the Markush implies for design-arounds
- Avoiding the entire genus likely requires changing at least one of the key constrained motifs (especially the phosphine oxide and the permitted heterocycle substitution positions/ring-closures).
- If a competitor stays within the same general chemotype, infringement risk remains high because biological framing (mutation selection and refractory/intolerant categories) is often satisfied by clinical use.
What ALK mutation types are covered by claim 1, and how do the later dependent mutation lists expand coverage?
Claim 1 mutation coverage (point mutations only; ALK-driven cancers)
Claim 1 targets ALK-driven cancers characterized by ALK mutation in SEQ ID NO: 2 with the mutation restricted to the following eight substitutions at specified amino-acid positions:
- Ile→Thr at position 1171
- Phe→Cys at position 1174
- Leu→Met at position 1196
- Ser→Arg at position 1206
- Glu→Lys at position 1210
- Phe→Cys at position 1245
- Gly→Ser at position 1269
- Val→Leu at position 1180
Additional ALK framing in claim 1
- ALK can be full-length ALK (claim 2).
- ALK can be an ALK-fusion product (claim 3).
- The method is tied to administering Formula (I) therapeutically.
Claim 4 mutation coverage (ALK-fusion protein; two specific substitutions)
Claim 4 is narrower in biological gating for ALK-fusion proteins:
- Phe→Val at 1174
- Tyr→Ser at 1278
Claim 5 mutation coverage (ALK mutant cell; five specific mutations)
Claim 5 covers inhibition for cells expressing ALK mutants with one of:
- Thr→Lys at 1151
- Leu→Val at 1152
- Cys→Tyr at 1156
- Ile→Ser at 1171
- Gly→Cys/Ser/Ala at 1269
Claim 6 mutation coverage (ALK-fusion protein mutant cell; two specific substitutions)
Claim 6 lists:
- Phe→Val at 1174
- Tyr→Ser at 1278
Claim 10 mutation coverage (extended list)
Claim 10 is an embodiment where a subject receives “compound 1” (and explicitly includes a structure reference). It lists, via claim 13 and claim 14, a broader mutation set.
Claim 13 provides an expanded mutation list including (positions and substitutions as stated):
- Thr at 1151 replacement
- Leu at 1152 replacement
- Cys at 1156 replacement
- Ile at 1171 replacement
- Phe at 1174 replacement
- Val at 1180
- Arg at 1181
- Leu at 1196, Leu at 1198
- Gly at 1202
- Asp at 1203
- Ser at 1206
- Glu at 1210
- Glu at 1241
- Phe at 1245
- Ile at 1268
- Gly at 1269
- insertion after 1151
Claim 14 adds further variants, including the ability to “convert” the mutation list to additional residue substitutions and insertion variants such as:
- Leu→Arg at 1152
- Cys→Tyr at 1156
- Ile→Ser / Ile→Asn / Ile→Thr at 1171
- Phe→Leu and Phe→Cys at 1174
- Val→Leu at 1180
- Leu→Met at 1196
- Gly→Arg at 1202
- Asp→Asn at 1203
- Ser→Tyr or Ser→Arg at 1206
- Glu→Lys at 1210
- Phe→Cys at 1245
- Gly→Ala or Gly→Ser at 1269
- insertion of Thr after 1151
Claim 15 then consolidates the broader set (claim 15 recites multiple mutations with the “wherein said mutation is selected from” list). That consolidation increases the chance that a competitor’s labeled patient subgroup falls within at least one independent/depended set depending on the asserted claim.
Implication for enforceability and challenge strategy
- If competitor tries to run clinical development focused on mutation subsets, the patent provides multiple entry points into those subsets across claims 1, 5, 10-17.
- For infringement defenses, the mutation-specific claims create clearer “no, they didn’t treat those mutants” routes; refractory/intolerant claims are broader.
What is the scope of “ALK-driven cancer refractory or intolerant” coverage in claim 7, 8, and 9?
Claim 7 (refractory to crizotinib, CH5424802, ASP3026)
Claim 7 covers an ALK-driven cancer that is refractory to one or more of:
- crizotinib
- CH5424802
- ASP3026
and requires administering Formula (I).
It also explicitly defines CH5424802 and ASP3026 “refers to the compound,” tying those names to the underlying comparator chemotypes described in the specification.
Claim 8 (intolerant to one or more of the same named inhibitors)
Claim 8 covers ALK-driven cancer in a subject intolerant to one or more of:
- crizotinib
- CH5424802
- ASP3026
and similarly administers Formula (I).
Claim 9 (refractory to inhibitor of wild-type ALK)
Claim 9 covers ALK-driven cancer refractory to an inhibitor of wild-type ALK.
Implication
Even if a competitor can avoid the specific mutation lists, claims 7-9 can still apply to broader patient populations defined by prior inhibitor failure/intolerance rather than genotype.
What generic entry risks exist for companies competing in ALK mutation space under US 9,611,283?
Key risk driver
Because the independent claims are method-of-treatment claims tied to a defined chemical genus, the risk to generic or follow-on entrants is highest where:
- Their compound is within Formula (I) and can be used in ALK patients with the covered mutation sets, or
- Their compound is administered in clinical contexts that match the refractory/intolerant frames.
Practical scenario framing
- If an entrant’s compound is near or within the same chemotype family, the mutation-specific and refractory/intolerant claims increase infringement pathways.
- If an entrant designs a different pharmacophore (for example, a different kinase-binding scaffold), literal infringement risk can drop, but doctrine-of-equivalents style arguments still follow chemotype boundaries, depending on claim construction and case history.
Litigation leverage points
- Mutation selectivity in the claims creates evidence focus for:
- biomarker testing records
- prescription patterns tied to the covered mutations
- trial protocols describing patient inclusion based on ALK mutation status.
How many separate claim “lanes” protect different clinical embodiments in US 9,611,283?
From the provided claim set, there are at least three overlapping protection lanes:
-
Genotype-specific lane
- Claim 1 mutation position set (8 substitutions)
- Claim 4 fusion pair
- Claim 5 cell inhibition mutation set (5 substitutions)
- Claim 6 fusion pair
- Claim 10-15 extended mutation lists including insertion
-
Clinical status lane
- Claim 7 refractory to crizotinib/CH5424802/ASP3026
- Claim 8 intolerant to crizotinib/CH5424802/ASP3026
-
Prior biology lane
- Claim 9 refractory to wild-type ALK inhibitor (mutation-independent trigger)
Each lane uses the same Formula (I) chemical limitation. That structure increases the odds that an accused product can match at least one lane in typical real-world prescribing and trial inclusion.
What formulations, dosing forms, and administration routes are protected?
Direct answer
The claim set provided is written as method-of-treatment claims with “therapeutically effective amount” and “administering” language but does not specify dosage forms, excipients, or routes in the excerpt.
Consequence for scope
- Literal protection is directed to the act of administration of Formula (I) in covered clinical settings rather than a fixed dosage form.
- In enforcement, this can allow broader application to oral, capsule, tablet, or other formulations if the compound itself is within Formula (I), subject to claim construction and other parts of the patent not shown here.
How does US 9,611,283 compare with other ALK patent strategies (mutation-specific vs class-expansive)?
Mutation-position specificity
This patent spends claim language enumerating multiple ALK residue substitutions and includes insertion language. This is more specific than many ALK method patents that cover ALK-driven cancers broadly without genotype lists.
Class-expansive clinical qualifier
The refractory/intolerant claims using crizotinib, CH5424802, and ASP3026 push toward real-world clinical sequences rather than purely biomarker-qualified cohorts.
Net effect
The estate is positioned to cover both:
- biomarker-driven use (mutation-specific lanes), and
- sequence-of-therapy use (refractory/intolerance lanes).
Key takeaways
- US 9,611,283 is a method-of-treatment patent whose infringement pivot is the match to Formula (I), defined by extensive Markush substituent variables, including a central —P(O)(R3A)(R3B) motif and multiple heterocycle substitutions/ring-closure rules.
- The patent creates multiple independent claim lanes: genotype-specific mutation lists (claims 1, 4-6, 10-15), plus clinical status lanes (refractory/intolerant to crizotinib/CH5424802/ASP3026 and refractory to wild-type ALK inhibitors).
- The largest business risk to competitors is not just chemical similarity but also how clinical use matches the claim-defined ALK mutation or treatment history qualifiers.
FAQs
1) What does the “inhibiting proliferation” claim language cover in US 9,611,283?
It covers contacting ALK mutant or ALK-fusion mutant expressing cells with Formula (I) in an amount sufficient to inhibit proliferation (claims 5 and 6).
2) Does US 9,611,283 require full-length ALK rather than ALK fusions?
No. The claims explicitly cover both full-length ALK (claims 2 and 11) and ALK-fusion proteins (claims 3, 4, 6, and related embodiments).
3) How are ALK mutant selections defined: only exact point mutations or also insertions?
The extended mutation lists include both point substitutions and an insertion of an amino acid after position 1151 (as stated in claim 13 and repeated in dependent recitations).
4) Are the refractory/intolerant claims limited to genotype-selected patients?
No. Claims 7 and 8 are framed by prior exposure status to named inhibitors, not by mutation position.
5) What is the principal design-around lever for a competitor?
The most direct lever is chemical: avoiding literal match to the Formula (I) Markush constraints, especially motifs like the phosphine oxide (—P(O)(R3A)(R3B)) and other ring/functional group restrictions; clinically, avoiding covered mutation subsets or covered refractory/intolerant treatment histories reduces the chance of matching the method qualifiers.
References (APA)
No external sources were provided or cited in the prompt.
